Innate Pharma reports first half 2020 financial results and business update
September 8, 2020Innate resumed enrollment of lacutamab TELLOMAK Phase 2 clinical trial for patients with Sézary syndrome and mycosis fungoides Monalizumab Phase 3 study expected to initiate in the second half of...Upcoming investor conferences
September 4, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) announces that it plans to participate in the following upcoming virtual investor conferences...Number of shares and voting rights of Innate Pharma as at August 1, 2020
August 12, 2020Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation,...Innate Pharma obtains €6.8M in public funding for its COVID-19 research and development activities
August 11, 2020Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today announced the Company has obtained funding of €6.8M under the PSPC-COVID call for...Innate Pharma announces publication of EXPLORE COVID-19 translational study findings in Nature
July 29, 2020New research suggests targeting C5a-C5aR1 axis could limit severe inflammatory response Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate ” or the “ Company ”) today...Innate Pharma announces the appointment of Joyson Karakunnel, MD, MSC, FACP as Chief Medical Officer
July 16, 2020Pierre Dodion, MD retires as Chief Medical Officer Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the appointment of Dr. Joyson...
